← all events raw scan snapshot Apr 26, 2026 — prices as of scan date, not live 65 rows · screens, not recommendations ported fromresearch/classic/scans/2026-04-26-healthcare-scan.md
ABT in near-capitulation (RSI 26), VEEV in freefall (-49% from high, -28% 3M), UNH bouncing violently from lows; medtech broadly weak; GRDN and CVS bright spots; LLY continues -22% from high but golden cross holds.
Quick Snapshot Signal Reading Overall 🟡 Mixed — medtech/diagnostics in pain; managed care volatile; pharma oversold opportunities emerging Key insight ABT RSI 26 with -34% from high (deepest oversold); VEEV -27% 30D worst in sector; UNH +7.65% this week from lows but -47% from 52wkHigh; GRDN +22% 3M is the standout
Price Table Surgical / Devices Stock Price 7D 30D 3M RSI vs SMA20 52wkHi% Trend Status Action ISRG $482.22 +2.6% +2.6% -8.81% 55.8 +4.4% -20.2% weak-up 🟡 Neutral 🔒 Hold SYK $347.24 +1.6% -0.4% -3.12% 55.8 +3.6% -14.2% strong-down 🟡 Neutral 🔍 Watch MDT $83.32 -3.95% -4.43% -16.55% 36.5 -3.2% -21.6% strong-down 🟡 Weak 🔍 Watch DXCM $61.57 -5.53% -7.88% -16.05% 39.9 -2.4% -31.6% strong-down 🟡 Weak 🔍 Watch ABT $91.13 -6.02% -12.53% -15.69% 26.3 -7.8% -34.5% strong-down 🟢 Oversold 🔍 Research
Large-Cap Pharma Stock Price 7D 30D 3M RSI vs SMA20 52wkHi% Trend Status Action LLY $883.96 -4.34% -3.53% -16.68% 38.3 -4.0% -22.1% down 🟡 Weak 🔍 Watch MRK $111.90 -5.61% -6.26% +4.96% 38.5 -5.5% -10.6% weak-down 🟡 Weak 🔍 Watch JNJ $227.50 -2.67% -5.18% +3.26% 35.8 -4.0% -9.6% weak-down 🟡 Weak 🔍 Watch PFE $27.19 +0.18% +2.18% +7.77% 49.2 -0.8% -5.4% strong-up 🟡 Neutral 🔒 Hold
Biotech / Oncology Stock Price 7D 30D 3M RSI vs SMA20 52wkHi% Trend Status Action GILD $130.40 -5.14% -5.68% -4.82% 30.9 -5.3% -17.1% weak-down 🟢 Oversold 📈 Accumulate AMGN $344.55 -2.49% -2.65% -0.79% 42.8 -1.2% -12.0% weak-down 🟡 Neutral 🔒 Hold BIIB $184.38 +0.82% -2.54% +6.5% 52.4 +2.0% -8.9% weak-down 🟡 Neutral 🔒 Hold VRTX $440.05 -0.56% -5.59% -2.11% 44.1 -1.6% -13.9% weak-down 🟡 Neutral 🔒 Hold MRNA $50.73 -8.2% -5.25% +5.71% 45.4 -2.0% -14.8% weak-down 🟡 Neutral 🔍 Watch
Managed Care / Insurance Stock Price 7D 30D 3M RSI vs SMA20 52wkHi% Trend Status Action UNH $313.00 +7.65% +9.64% -5.83% 67.6 +10.7% -47.5% up 🟠 Volatile 🔍 Watch CVS $77.94 +1.19% +8.93% -6.25% 56.6 +3.5% -8.5% strong-up 🟢 Strong 🔒 Hold
Healthcare IT / Life Sciences Stock Price 7D 30D 3M RSI vs SMA20 52wkHi% Trend Status Action VEEV $158.45 -13.25% -14.48% -27.6% 32.9 -9.4% -49.0% strong-down 🟡 Approaching 🔍 Research TMO $514.23 +1.59% +9.41% -17.22% 58.9 +5.8% -20.2% weak-up 🟡 Neutral 🔒 Hold GRDN $37.57 -1.34% +2.93% +22.58% 54.0 -0.5% -9.2% strong-up 🟢 Strong 🔒 Hold IQV $162.28 -8.23% -2.03% -32.22% 38.6 -5.1% -34.3% strong-down 🟡 Weak 🔍 Watch
Tier Analysis RSI < 30 — Capitulation Zone Stock Price RSI 30D% 52wkHi% Notes ABT $91.13 26.3 -12.53% -34.5% Medical devices/diagnostics, death cross; -34% from high; tariff + consumer health fear
RSI 30–40 — Oversold / Entry Zone Stock Price RSI 30D% 52wkHi% Notes GILD $130.40 30.9 -5.68% -17.1% Golden cross intact; HIV franchise + oncology pipeline VEEV $158.45 32.9 -14.48% -49.0% Healthcare cloud software, -27% 3M; death cross; structural or sentiment? JNJ $227.50 35.8 -5.18% -9.6% Diversified pharma, golden cross; -10% from high; litigation resolved MDT $83.32 36.5 -4.43% -21.6% Medtech, death cross; -22% from high; cardiac devices under pressure LLY $883.96 38.3 -3.53% -22.1% GLP-1 leader, golden cross; -22% from high; best quality name in this tier MRK $111.90 38.5 -6.26% -10.6% Keytruda franchise, golden cross; +5% 3M recently reversing; watch IQV $162.28 38.6 -2.03% -34.3% CRO/healthcare IT, death cross; -32% 3M — sector headwinds DXCM $61.57 39.9 -7.88% -31.6% CGM leader, death cross; competition from Abbott intensifying
RSI 40+ — Neutral to Strong Stock Price RSI 30D% Notes LLY $883.96 38.3 — Borderline — see above AMGN $344.55 42.8 -2.65% Biosimilar exposure; stable VRTX $440.05 44.1 -5.59% CF franchise; consolidating PFE $27.19 49.2 +2.18% Turnaround trade; cost cuts working BIIB $184.38 52.4 -2.54% Alzheimer's optionality GRDN $37.57 54.0 +2.93% Strong-up, +22% 3M — best momentum TMO $514.23 58.9 +9.41% Life sciences tools bounce CVS $77.94 56.6 +8.93% Pharmacy benefit recovery UNH $313.00 67.6 +9.64% Violent bounce from -47% — wait for confirmation
Entry Zones EXTREME OVERSOLD (RSI < 30) Stock Current Zone RSI 30D Action Notes ABT $91.13 <$92 26.3 -12.53% 🔍 Research RSI 26 + death cross = do NOT buy until trend changes; watch for RSI divergence
OVERSOLD (RSI 30–40) — Selective Entry Stock Current Zone RSI 30D Action Notes GILD $130.40 <$130 30.9 -5.68% 📈 Accumulate Golden cross intact; HIV monopoly + oncology; -17% from high LLY $883.96 <$880 38.3 -3.53% 📈 Accumulate GLP-1 secular leader; golden cross; -22% from high; best risk/reward in pharma JNJ $227.50 <$225 35.8 -5.18% 📈 Accumulate Diversified; golden cross; dividend aristocrat; -10% from high VEEV $158.45 <$155 32.9 -14.48% 🔍 Research Death cross + -49% from high; need to understand structural vs sentiment damage
Action Matrix Action Stocks Why 📈 ACCUMULATE GILD, LLY, JNJ RSI 31-38, golden cross, quality franchises; oversold in otherwise healthy companies 🔍 RESEARCH ABT, VEEV, IQV RSI 26-39 but with death crosses and structural questions — need catalyst or trend change 🔒 HOLD AMGN, BIIB, VRTX, PFE, ISRG, TMO, CVS, GRDN Stable thesis; various neutral-to-recovering trends 🔍 WATCH MRK, MDT, DXCM, UNH, SYK, MRNA Pull-backs in quality names; monitor for RSI confirmation ⚠️ CAUTION UNH -47% from high with volatile +7.65% weekly bounce; wait for RSI/trend stabilization before adding
What Changed vs 2026-04-10 Stock Apr 10 Apr 26 16D Move Note ABT Not scored $91.13 / RSI 26 — New capitulation alert — deepest oversold in healthcare VEEV ~$185 / RSI ~42 $158.45 / RSI 33 -14.3% Accelerating breakdown; death cross confirmed GILD $140.70 / RSI 50 $130.40 / RSI 31 -7.3% Entered oversold — upgraded to accumulate UNH ~$285 / RSI ~40 $313.00 / RSI 68 +9.9% Violent bounce — RSI 68 from near-oversold in 16 days LLY $939.32 / RSI 47 $883.96 / RSI 38 -5.9% Continued decline; approaching oversold entry zone JNJ Not scored $227.50 / RSI 36 — New watch — quality pharma reaching entry zone GRDN $39.38 / RSI 64 $37.57 / RSI 54 -4.6% Small pullback from Apr 10 highs; trend remains strong-up IQV Not scored $162.28 / RSI 39 — New watch — CRO sector -32% 3M; structural pressure CVS Not scored $77.94 / RSI 57 — Outperforming; strong-up trend emerging MDT In Apr 10 $83.32 / RSI 37 Continued decline Death cross confirmed; no change to avoid thesis
Key Discoveries Discovery Implication ABT RSI 26 with death cross — deepest in sector Medical device demand destruction or tariff-driven; do NOT buy before trend change VEEV -49% from high yet RSI only 33 Healthcare cloud SaaS has structural headwinds beyond market volatility UNH +7.65% week on -47% from high stock Managed care volatility creating whipsaws — not a clean entry until RSI < 40 again GRDN +22% 3M while broader healthcare weak Guardian Health's outperformance = undiscovered health system automation story GILD/JNJ/LLY all RSI 31-38 simultaneously Rare triple-oversold in quality pharma — selective accumulation window
Open Questions
ABT : Is the -34% from high driven by tariffs on imported device components, or broader diagnostic demand collapse?VEEV : At -49% from high with RSI 33, is this bottoming or a value trap (EHR consolidation risk)?UNH : +7.65% single week from RSI near-oversold — short squeeze, fundamental repair, or dead-cat?IQV /DHR correlation: two CRO-adjacent names both -30%+ 3M — is this a sector call on clinical trial slowdown?
No direct external sources are attached to this read.